Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D3.316 - Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia
D3.305 - Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety
D3.306 - Successful treatment of severe atopic dermatitis in teenage patient with hyper-IgE syndrome (STAT3 mutation)
D3.307 - Experience with Systemic Emergent Therapies for Moderate-to-Severe Atopic Dermatitis: Insights from an Allergy and Clinical Immunology Department
D3.308 - Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort
D3.309 - Challenges in HAE therapy in children
D3.310 - Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis
D3.311 - Screening for Hereditary Angioedema in Pediatric Patients with Autoinflammatory Diseases and Chronic Abdominal Pain
D3.312 - Lymphatic supplementation improves atopic dermatitis in dogs
D3.313 - Chronic Spontaneous Urticaria and its relationship with Allergies to Aerogenic Fungi: dermographism, skin hyperreactivity, and chemical patterns of inflammation
D3.314 - Sensitization Profile in Patch Tests with the Portuguese Baseline Series in the Algarve
D3.315 - Airborne allergic contact dermatitis to dry shampoo
D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023
D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters
D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch
D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria
D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway
D2.300 - Fixed Drug Eruption related to the use of NSAIDs
D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test
D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download